Drugs / AV078
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06205381 | Jan 2024 → Feb 2025 | — | Aeovian Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07680322 | Sep 2026 → Sep 2027 expected | epilepsy, tuberous sclerosis | Aeovian Pharmaceuticals, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AV078 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205381 ↗ |
| Action | Inhibit | “AV078, a selective inhibitor of mammalian target of rapamycin complex 1 (mTORC1)” NCT06205381 ↗ |
| Route | Oral | “AV078 oral solution” NCT06205381 ↗ |